| Literature DB >> 19751498 |
Milla Pietiäinen1, Patrice François, Hanne-Leena Hyyryläinen, Manuela Tangomo, Vera Sass, Hans-Georg Sahl, Jacques Schrenzel, Vesa P Kontinen.
Abstract
BACKGROUND: Understanding how pathogens respond to antimicrobial peptides, and how this compares to currently available antibiotics, is crucial for optimizing antimicrobial therapy. Staphylococcus aureus has several known resistance mechanisms against human cationic antimicrobial peptides (CAMPs). Gene expression changes in S. aureus strain Newman exposed to linear CAMPs were analyzed by DNA microarray. Three antimicrobial peptides were used in the analysis, two are derived from frog, temporin L and dermaseptin K4-S4(1-16), and the ovispirin-1 is obtained from sheep.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19751498 PMCID: PMC2748101 DOI: 10.1186/1471-2164-10-429
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Genes induced by cationic antimicrobial peptides.
| SA0011 | ||||||
| SA0122 | ||||||
| SA0205 | ||||||
| SA0344 | ||||||
| SA0428 | ||||||
| SA0430 | ||||||
| SA0480 | ||||||
| SA0513 | ||||||
| SA0591 | ||||||
| SA0677 | ||||||
| SA0781 | ||||||
| SA0817 | ||||||
| SA0825 | ||||||
| SA0835 | ||||||
| SA0845 | ||||||
| SA0903 | ||||||
| SA1164 | ||||||
| SA1170 | ||||||
| SA1216 | ||||||
| SA1219 | ||||||
| SA1227 | ||||||
| SA1254 | ||||||
| SA1476 | ||||||
| SA1517 | ||||||
| SA1545 | ||||||
| SA1549 | ||||||
| SA1599 | ||||||
| SA1655 | ||||||
| SA1659 | ||||||
| SA1701 | ||||||
| SA1820 | ||||||
| SA1836 | ||||||
| SA1862 | ||||||
| SA1990 | ||||||
| SA2113 | ||||||
| SA2221 | ||||||
| SA2304 | ||||||
| SA2324 | ||||||
| SA2343 | ||||||
| SA2397 | ||||||
| SA2467 | ||||||
| SA2492 | ||||||
| SAS016 | ||||||
*: Only the most strongly upregulated genes, the marker genes of the CAMP stimulon, are shown in this table. The complete list of genes induced at least 2-fold by several CAMPs is shown in additional file 1. In the case of operons, only the first gene or the most strongly induced gene is shown;
**: T, temporin L-NH2; O, ovispirin-1-NH2; D, dermaseptin K4-S4(1-16)-NH2;
***: VCM, vancomycin inducible; VraSR, belongs to the VraSR regulon.
Figure 1Induction or repression of genes in cells treated with cationic antimicrobial peptides as determined by qRT-PCR. The measurements of a set of differentially expressed genes were performed after 10 min treatments. The standard deviations of SAS016 are 19 (temporin L-NH2) and 53 (ovispirin-1-NH2). The standard deviation of vraD (ovispirin-1-NH2) is 6.
Induction of vraD, SA0205, prsA and groEL in S. aureus cells treated with peptides or cell wall-active antibiotics.
| Ovispirin-1 | 3.7 (0.5) | 5.1 (1.0) | 7.2 (1.6) | 2.5 (0.5) |
| Ovispirin-1-NH2 | 136.7 (8.7) | 20.0 (0.7) | 30.7 (1.7) | 3.8 (0.4) |
| Temporin-L-NH2 | 4.6 (1.3) | 15.1 (3.6) | 6.4 (1.8) | 4.0 (0.1) |
| Bacitracin | 467.5 (15.3) | 51.4 (0.8) | 27.9 (4.5) | 3.6 (0.1) |
| Vancomycin | 6.6 (0.6) | 25.5 (1.8) | 32.7 (1.7) | 1.9 (0.0) |
| Teicoplanin | 2.5 (0.3) | 35.7 (6.9) | 32.1 (4.1) | 3.0 (0.3) |
| Pentaglysin | 1.0 (0.0) | 1.3 (0.1) | 1.3 (0.0) | 1.1 (0.0) |
*: The ratio of the expression level of the gene in S. aureus Newman treated for 10 minutes with the antimicrobial agent or peptide to that in untreated cells as determined by qRT-PCR. The induction ratios are means from three experiments. The standard deviations are in parenthesis;
**: The concentrations of the antimicrobials and peptides used in the analysis are 5 × MIC (see Table 3) with the exception of temporin-L-NH2, which was used at a subinhibitory concentration, and pentaglycine, which was not microbicidal at the 20 μg/ml concentration.
Antimicrobial sensitivity of the ΔvraDE and ΔvraSR mutants and their parental strain S. aureus Newman.
| Ovispirin-1 | 20 | 20 | 20 |
| Ovispirin-1-NH2 | 10 | 20 | 20 |
| Temporin L-NH2 | 6 | 6 | 6 |
| Nisin | 6.25 | 6.25 | 6.25 |
| Bacitracin | 5 | 2.5 | 20 |
| Daptomycin | 2.5 | 2.5 | 2.5 |
| Teicoplanin | 0.125 | 0.5 | 0.5 |
| Vancomycin | 1 | 1 | 1 |
Induction of vraD, SA0205, prsA and groEL in S. aureus ΔvraSR and ΔvraDE mutants treated with vancomycin.
| Δ | 7.9 (0.2) | 2.5 (0.2) | 3.2 (0.1) | 2.1 (0.1) |
| Δ | not expressed | 60.4 (2.1) | 36.0 (0.7) | 3.1 (0.4) |
| wild type | 6.6 (0.6) | 25.5 (1.8) | 32.7 (1.7) | 1.9 (0.0) |
*: The ratio of the expression level of the gene in the mutant or the wild-type strain treated for 10 minutes with 5 μg/ml of vancomycin to that in untreated cells as determined by qRT-PCR. The induction ratios are means from three experiments. Standard deviations are in parenthesis.
Figure 2Increased sensitivity of the Δ. The ΔvraRS mutant and the wild-type S. aureus Newman strain were grown either in the presence or absence of the antimicrobial agents as indicated in 150 μl of BHI medium in wells of microtiter plates in a Bioscreen for 16 hours. The optical densities of the cultures were measured every 15 minutes. The data points show the densities measured at one-hour intervals.
Bacterial strains and plasmids.
| 5-alpha | cloning strain | New England Biolabs |
| Newman | ATCC25904, methicillin susceptible | [ |
| RN4220 | NCTC 8325-4-r, restriction negative strain | [ |
| COL | methicillin resistant (MRSA) | [ |
| RH7657 | Newman Δ | this study |
| RH7661 | Newman Δ | this study |
| RH7788 | RN4220 Δ | this study |
| RH7790 | RN4220 Δ | this study |
| pGEM-3zf(+) | cloning vector, ampr ( | Promega |
| pKOR1 | gene replacement vector, ampr ( | [ |
| pKTH3762 | pGEM-3zf(+) containing the | this study |
| pKTH3763 | pKOR1 containing the | this study |
| pKTH3764 | pGEM-3zf(+) containing the | this study |
| pKTH3765 | pKOR1 containing the | this study |